(Q34334039)

1 August 2017

Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. (English)

1 reference

1 August 2017

3

Alexander Bystritsky

1 reference

1 August 2017

Murray B Stein

1

1 reference

1 August 2017

Mark H Pollack

series ordinal

2

1 reference

1 August 2017

Jeffrey E Kelsey

series ordinal

4

1 reference

1 August 2017

Richard M Mangano

series ordinal

5

1 reference

1 August 2017

16 July 2004

1 reference

1 August 2017

1 reference

1 August 2017

177

1 reference

1 August 2017

280-288

1 reference

1 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1007/s00213-004-1957-9

1 August 2017

0 references

cites work

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies.

1 reference

12 December 2020

Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group

1 reference

12 December 2020

The validity and reproducibility of a work productivity and activity impairment instrument

1 reference

12 December 2020

Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study.

1 reference

12 December 2020

Social phobia symptoms, subtypes, and severity: findings from a community survey.

1 reference

12 December 2020

Disability and quality of life in social phobia: epidemiologic findings.

1 reference

12 December 2020

Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study.

1 reference

12 December 2020

Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study.

1 reference

12 December 2020

Quality of care for primary care patients with anxiety disorders.

1 reference

12 December 2020

Social phobia. Comorbidity and morbidity in an epidemiologic sample.

1 reference

12 December 2020

Establishment of remission criteria for anxiety disorders.

1 reference

12 December 2020

Social anxiety disorder and the risk of depression: a prospective community study of adolescents and young adults.

1 reference

12 December 2020

Unmasking social anxiety disorder

1 reference

12 December 2020

Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study.

1 reference

12 December 2020

Psychometric properties of the Social Phobia Inventory (SPIN). New self-rating scale.

1 reference

12 December 2020

Social phobia subtypes in the National Comorbidity Survey.

1 reference

12 December 2020

Social phobia in the primary care medical setting.

1 reference

12 December 2020

Venlafaxine in social phobia.

1 reference

12 December 2020

The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10

1 reference

12 December 2020

Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment.

1 reference

12 December 2020

Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.

1 reference

12 December 2020

Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial.

1 reference

12 December 2020

Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

1 reference

12 December 2020

Antidepressants for generalised anxiety disorder (GAD)

1 reference

12 December 2020

A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder.

1 reference

12 December 2020

Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey.

1 reference

12 December 2020

Lifetime co-morbidities between social phobia and mood disorders in the US National Comorbidity Survey

1 reference

12 December 2020

Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome.

1 reference

12 December 2020

Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study.

1 reference

12 December 2020

Social anxiety disorder

1 reference

12 December 2020

Impact of generalized social anxiety disorder in managed care.

1 reference

12 December 2020

Phenelzine vs atenolol in social phobia. A placebo-controlled comparison.

1 reference

12 December 2020

Modelling the population cost-effectiveness of current and evidence-based optimal treatment for anxiety disorders.

1 reference

12 December 2020

Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder.

1 reference

12 December 2020

Functional impairment in social phobia

1 reference

12 December 2020

Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study.

1 reference

12 December 2020

A rating scale for depression

1 reference

12 December 2020

Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study.

1 reference

12 December 2020

Quality of life in individuals with anxiety disorders.

1 reference

12 December 2020

Psychometric properties of the Liebowitz Social Anxiety Scale.

1 reference

12 December 2020

Delineating social phobia

1 reference

12 December 2020

Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression.

1 reference

12 December 2020

10.1007/S00213-004-1957-9

Identifiers

DOI

1 reference

Dimensions Publication ID

1 August 2017

0 references

1 reference